$20.00
+1.8%Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Wall Street analysts project that BCAX stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 28.60, with estimates ranging from a low of 18.00 to a high of 42.00.
The consensus 1-year price target stands at 28.60, with estimates ranging from a low of 18.00 to a high of 42.00.
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Favorable risk-reward. Potential upside significantly exceeds downside risk, offering asymmetric return profile attractive for risk-tolerant investors.
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Significant contraction projected—major business challenges or industry disruption likely.
Wide estimate range reveals significant forecast uncertainty and potential volatility.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Declining estimates with wide disagreement: Analysts projecting contraction without consensus signals significant business uncertainty—exercise caution.
Significant contraction projected—major business challenges or industry disruption likely.
Moderate coverage—sufficient for guidance but may lack depth of large-cap analysis.
Wide estimate range reveals significant forecast uncertainty and potential volatility.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Declining estimates with wide disagreement: Analysts projecting contraction without consensus signals significant business uncertainty—exercise caution.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Significant contraction projected—major business challenges or industry disruption likely.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
During the last 12 months, insiders have purchased $4.83M and sold $3.53M worth of BCAX shares, resulting in $1.30M of net buying activity.
0
0.00
108.4K
2.25M
-2.3M
-$2.25M
300.0K
4.80M
43.5K
797.08K
+4.0M
+$4.00M
8.0K
30.32K
26.4K
485.45K
-455K
-$455K
0
0.00
0
0.00
+0
+$0
Ra Capital Management, L.P.
Director, 10 Percent Owner:
$4.80M
Cohlhepp Ryan
Director, Officer: President And Coo
$30K
Cohlhepp Ryan
Director, Officer: President And Coo
$1.16M
Hyep Ivan
Officer: Chief Financial Officer
$1.11M
Mazumdar Claire
Director, Officer: Chief Executive Officer
$1.03M
Raben David
Officer: Chief Medical Officer
$230K
Moderately bullish with $1.30M net buying. Insiders show cautious optimism through measured share purchases.
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
4 insider sellers vs. 2 buyers. More insiders selling than buying suggests cautious or negative sentiment.
Continue your BCAX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.